FREE Daily Stock Alerts From Stock-PR.com
Cephalon Inc. (Nasdaq:CEPH) is sad to announce that its founder, Chairman and Chief Executive Officer, Frank Baldino, Jr., Ph.D. passed away Thursday evening, December 16, 2010. A pioneer in the biotechnology industry, he was an inspirational leader who will be sorely missed. The Cephalon organization mourns his passing and extends its sympathies to the entire Baldino family.
Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients.
Power3 Medical Products, Inc. (OTC:PWRM)
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” stated Dr. Ira L. Goldknopf, PWRM’s President & Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
Power3 Medical Products, Inc. recently filed several patent applications that are currently pending for its NuroPro technology. PWRM also has a world-wide exclusive license from Baylor College of Medicine in Houston, Texas. To date, PWRM has given nine presentations on NuroPro at international scientific meetings in the United States, Europe and China. PWRM has also published six articles on NuroPro in peer-reviewed scientific journals. PWRM intends to publish these latest findings as well.
Power3 Medical Products, Inc., founded in 1992 and based in The Woodlands, Texas, is a bio-technology company that engages in the development and marketing of diagnostic tests in the fields of neurodegenerative and neuromuscular diseases and cancer in the U.S. Power3 Medical Products, Inc.’s products include NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease; and BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer. Power3 Medical Products, Inc.’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy.
To learn more about PWRM visit: http://www.Power3Medical.com
Medtronic, Inc. (NYSE:MDT) announced this month that the U.S. Food and Drug Administration (FDA) has approved its Arctic Front Cardiac CryoAblation Catheter system, the first and only Cryoballoon in the United States indicated for the treatment of drug refractory paroxysmal atrial fibrillation (NYSEARCA:PAF). The Cryoballoon treatment involves a minimally-invasive procedure that efficiently creates circumferential lesions around the pulmonary vein, which is the source of erratic electrical signals that cause the irregular heartbeat.
Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company’s Cardiac Rhythm Disease Management segment offers products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, and cardiac pacemakers; AF products; diagnostics and monitoring devices; and patient management tools.
American Video Teleconferencing Corp. (OTCPK:AVOT)
American Video Teleconferencing Corp. is pleased to announce that it has hired a French speaking geologist to search the archives of the Quebec Department of Mines for Rare Earths showings not on a current computer file. AVOT believes the rare earths industry is where it wants to maintain a very strong focus and is looking to expand its holdings. As neither the Federal nor Quebec Governments have carried out any air borne surveys in this area, AVOT will seek a contractor to do an air borne Mag-EM radiometric survey. This survey will cover its present holdings and the immediate surrounding area looking for future acquisitions. We are pleased to be working in the Province of Quebec as it is rated the number one jurisdiction in the world to carry out mineral exploration. The Quebec Government gives a rebate up to 45% for property expenditures.
In other company news, AVOT is seeking a contractor to do an air borne Mag-EM radiometric survey for its present holdings and the immediate surrounding area looking for future acquisitions. AVOT is pleased to be working in the Province of Quebec as it is rated the number one jurisdiction in the world to carry out mineral exploration. The Quebec Government gives a rebate up to 45% for property expenditures.
Presently AVOT is in the final stage of negotiations with Kondor Gold Pyt. in Australia.
AVOT is aggressively carrying out searches world-wide for opportunities in Precious, Base and Rare Earths metal projects.
Furthermore, American Video Teleconferencing Corp. is pleased to announce that it has signed an option agreement to acquire two claim blocks in townships of Mekinac and Lajuene, Province of Quebec. These claim blocks are approximately 3600 acres in total and are located 120 miles east of Montreal P.Q. and 50 miles north of Three Rivers P.Q. They are accessible year round with infrastructure in the immediate vicinity. The claims adjoin a property that had one of the highest readings of Rare Earths in North America. Sampling in the 1950s gave readings of 48% combined Cerium, Lanthanum, Neoymium and Yttrium. That property has remained dormant for over 50 years but the new owners plan an extensive exploration program this fall.
AVOT, after a lengthy search and after careful due diligence, believes this is going to be one of the most active areas for Rare Earths exploration and our holdings are in the same geological setting as the 48% Rare Earths showing. Rare Earths are in huge demand especially in the United States as China is closing off its exports of these strategic metals to less than 5% of its production.
Teck Resources Limited (NYSE:TCK) recently announced the expiration and final results of its previously announced modified "Dutch Auction" cash tender offer (the "Tender Offer") for the notes listed in the table below (together, the "Notes"). Teck accepted US$650 million aggregate principal amount of Notes for purchase in the Tender Offer and expects to make payment for the accepted Notes on December 17, 2010. Based on the terms of the Tender Offer, the clearing premium is determined to be US$30.00 per US$1,000 principal amount of Notes. The Tender Offer is oversubscribed resulting in Notes tendered at the clearing premium being pro rated based on a pro ration factor of 0.27229297.
Teck Resources Limited operates as a diversified mining, mineral processing, and metallurgical company. It involves in a range of activities related to mining, including exploration, development, smelting, refining, safety, environmental protection, product stewardship, recycling, and research. The company primarily produces copper, metallurgical coal and zinc, molybdenum, and specialty metals.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM). Crown Equity Holdings Inc. (OTCPK:CRWE) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (OTCPK:AVOT) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services.
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________Be Sure To Visit stock-pr.ning.com
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.